drugset / Trial / NCT03725267
Melatonin for Renal Protection in Patients Receiving Polymyxin B
Phase 2
Terminated
88 enrolled
Hospital de Clinicas de Porto Alegre
Conselho Nacional de Desenvolvimento Científico e Tecnológico · collabPontificia Universidade Católica do Rio Grande do Sul · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study has the objective to evaluate the effect in renal function of 30mg of Melatonin versus placebo in patients ≥18 years old treated with polymyxin B. The development of nephrotoxicity will be evaluated by RIFLE(Risk, Injury, Failure, Loss, End stage renal disease) score and KIM-1 urinary biomarker for the first 14 days of polymyxin B therapy.
Timeline
- Start
- 2018-10-01
- Primary completion
- 2021-06-15
- Completion
- 2021-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melatonin | Small molecule | 30 mg | — |